Stribild Injuries
The FDA is warning that individuals taking Gilead’s HIV drug Stribild could experience kidney disease or bone density loss. Gilead knew its drug was dangerous, yet released it to the market anyway. There are multiple less toxic versions on the market, yet Gilead wanted to increase its profits instead of helping those struggling with HIV.
Read MoreAtripla Injuries
The FDA is warning that individuals taking Gilead’s HIV drug Atripla could experience bone density complications. Gilead knew its drug was dangerous, yet released it to the market anyway. There are multiple less toxic versions on the market, yet Gilead wanted to increase its profits instead of helping those struggling with HIV. About Atripla
Read More
TDF Medication Dangers for the LGBTQIA Community
Gilead’s HIV drug tenofovir disoproxil fumarate (TDF) is paramount to those in the LGBTQIA community living with HIV. It also helps those wanting to prevent transmission who take it as PrEP. People trusted Gilead to keep them safe, but no one knew the TDF medication dangers since the company hid it from everyone. About
Read More
Bone Density Injuries Linked to Gilead HIV Medications
The FDA is warning that individuals taking Gilead’s HIV drug tenofovir disoproxil fumarate (TDF) could experience bone density loss. Gilead knew its drug was dangerous, yet the company released it anyway. There are multiple less toxic versions on the market, yet Gilead wanted to increase its profits instead of helping those struggling with HIV.
Read More
Kidney Issues Linked to Gilead TDF Meds
The FDA is warning that individuals taking Gilead’s HIV drug tenofovir disoproxil fumarate (TDF) could experience kidney disease. Gilead knew its drug was dangerous, yet the company released it anyway. There are multiple less toxic versions on the market, yet Gilead wanted to increase its profits instead of helping those struggling with HIV. About TDF
Read More